Clinical Trial: Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824701) titled 'Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas' on Jan. 16.

Brief Summary: The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Intervention: DRUG: Tazemetostat

Tazemetostat will be self-administered BID as an oral treatme...